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Abstract
Background: Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in
gynecological malignancies. PD-1/PD-L1 blockade in gynecological cancers showed objective responses in 13–17%
of patients. This could be due to immunosuppressive effects exerted by gynecological tumors on the
microenvironment and an altered tumor vasculature.
In other malignancies, combining checkpoint blockade with radiation delivers benefit that is believed to be due to
the abscopal effect. Addition of immune modulation agents has also shown to enhance immune checkpoint
blockade efficacy. Therefore we designed a regimen consisting of PD-1 blockade combined with radiation, and
different immune/environmental-targeting compounds: repurposed drugs, metronomic chemotherapy and a food
supplement.
We hypothesize that these will synergistically modulate the tumor microenvironment and induce and sustain an
anti-tumor immune response, resulting in tumor regression.
Methods: PRIMMO is a multi-center, open-label, non-randomized, 3-cohort phase 2 study with safety run-in in
patients with recurrent/refractory cervical carcinoma, endometrial carcinoma or uterine sarcoma.
Treatment consists of daily intake of vitamin D, lansoprazole, aspirin, cyclophosphamide and curcumin, starting 2
weeks before the first pembrolizumab dose. Pembrolizumab is administered 3-weekly for a total of 6 cycles.
Radiation (3 × 8 Gy) is given on days 1, 3 and 5 of the first pembrolizumab dose.
The safety run-in consists of 6 patients. In total, 18 and 25 evaluable patients for cervical and endometrial
carcinoma respectively are foreseen to enroll. No sample size is determined for uterine sarcoma due to its rarity.
The primary objective is objective response rate at week 26 according to immune-related response criteria.
Secondary objectives include safety, objective response rate at week 26 according to RECIST v1.1, best overall
response, progression-free survival, overall survival and quality of life.
Exploratory, translational research aims to evaluate immune biomarkers, extracellular vesicles, cell death biomarkers
and the gut microbiome.
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Discussion: In this study, a combination of PD-1 blockade, radiation and immune/environmental-targeting
compounds is tested, aiming to tackle the tumor microenvironment and induce anti-tumor immunity. Translational
research is performed to discover biomarkers related to the mode of action of the combination.
Trial registration: EU Clinical Trials Register: EudraCT 2016-001569-97, registered on 19-6-2017. Clinicaltrials.gov:
NCT03192059, registered on 19-6-2017.
Keywords: PD-1 blockade, Radiation, Immune modulation, Tumor microenvironment, Cervical carcinoma,
Endometrial carcinoma, Uterine sarcoma, Drug repurposing, Metronomic chemotherapy, Financial toxicity
Background
Cervical cancer (CC) is the 3rd most common malig-
nancy and the 4th most common cause of cancer-related
deaths in women [1]. Early stage disease can often be
cured with surgery and/or chemoradiation and has a
good prognosis [2]. For women with extrapelvic disease,
the 5-year survival rate is only 17%. For women with re-
current disease, prognosis is even worse with 5-year sur-
vival rates of less than 5% [3]. Persistent infection with
human papilloma virus (HPV) is an essential step in the
development of most cervical cancers [4]. In the
KEYNOTE-158 trial, administration of Pembrolizumab
in 98 pretreated, advanced cervical cancer patients re-
sulted in an ORR of 13.3% (95% CI, 7.3–21.6%) and
16.0% (95% CI, 8.8–25.9%) in the whole and
PD-L1-positive cohort (n = 81) respectively [5].
Endometrial cancer (EC) is the 5th most common ma-
lignancy in women [6]. Most ECs are diagnosed at an
early stage (75%) and only a minority of these (2–15%)
experience disease recurrence. When EC is diagnosed at
late stages (25%) or has an aggressive histology, the
chance of recurrence is very high (50%) [7]. The progno-
sis for patients with recurrent disease is dismal, empha-
sizing the high unmet need for this patient population
[8]. In the phase 1b KEYNOTE-028 cohort of patients
with PD-L1 positive advanced EC, 13% of patients
achieved a partial response and another 13% achieved
stable disease upon Pembrolizumab treatment. However,
polymerase ε (POLE)-mutated and microsatellite insta-
ble (MSI) EC subgroups recently demonstrated en-
hanced infiltration of CD8+, PD-1+ and PD-L1+ immune
cells [9–11]. Encouraging case reports with immune
checkpoint blockade (ICB) provided proof of principle in
both tumor subgroups [12, 13] and Pembrolizumab was
FDA approved for all MSI+ tumors. However,
POLE-mutated and MSI EC constitute only a minority
of patients with recurrent EC.
Uterine sarcomas (US) are a very rare and aggressive
cancer type, comprising around 3–4% of all uterine can-
cers. Standard treatment consists of surgery. The avail-
able cytotoxic therapies show very little clinical benefit,
which is reflected by the 5-year survival rates, ranging
from 57 to 65% for stage I disease to 9–26% for stage IV
disease [14, 15]. PD-1 blockade in uterine sarcoma has
been pursued in limited numbers of patients, but with-
out major responses [16–18].
Clearly, immunotherapy data in CC and EC are lim-
ited. Response rates of around 15% are encouraging but
not enough in this poor prognostic population. Evidence
is pointing towards a crucial role of the tumor micro-
environment (TME) in modulating an anti-tumor im-
mune response, urging for combinatorial approaches to
improve responses to ICB [19, 20].
Recent pre-clinical and clinical data indicate that the
combination of radiotherapy (RT) with ICB showed ac-
ceptable toxicity [21, 22] and could potentiate the in situ
vaccine effect of radiotherapy, mainly when given con-
comitant, but not sequential [23–25]. In addition, it has
been described that RT induces immune cell recruit-
ment into the tumor by releasing chemokines, thereby
altering the TME [25–27].
In an attempt to further modulate the TME in an inex-
pensive manner, we added repurposed compounds (i.e.
drugs approved for another indication) with (immune)
modulating properties. The proposed mode of action of
the combination is depicted in Fig. 1. Vitamin D is able to
increase immune cell infiltration and reduce suppressive
CD34+ cells in human tumors [28–32] and inhibits cancer
stem cells [33, 34]. Aspirin acts by counter-acting COX
activity [35–37] and by favoring an overall anti-angiogenic
balance [38]. Lansoprazole, a proton-pump inhibitor, is
added to inhibit tumor acidosis, thereby improving
intratumoral immune cell function [39–42]. Low-dose
cyclophosphamide exerts immunostimulatory and antian-
giogenic effects [43–45]. Curcumin is a food supplement
with radiosensitizing and anti-inflammatory properties
[46–48].
The current phase II trial aims at exploring the thera-
peutic efficacy of the combination of PD-1 blockade with
RT and immune/TME modulation. Considering the un-
known toxicity profile of this combination, a safety
run-in is performed. Given the high economical cost of
PD-1 inhibitors, it is of utmost importance to identify
patients who are likely to respond to these treatments
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beforehand. Therefore, the study is accompanied by a
translational research package to evaluate immune re-
sponse biomarkers in blood and tumor, characterize
extracellular vesicles, explore cell death biomarkers in
blood and analyze the relationship with the gut
microbiome.
Methods/design
Objectives
Primary objective
To evaluate the efficacy of the treatment, which will be
assessed as the objective response rate (ORR) at week 26
according to immune-related response criteria (irRC).
Secondary objectives
Safety according to Common Terminology Criteria for
Adverse Events (CTCAE4.0), the ORR at week 26 ac-
cording to RECIST criteria, the best overall response
(BOR), progression-free survival (PFS), overall survival
(OS) and quality of life (QoL).
Exploratory objectives
Exploratory objectives will be evaluated in the transla-
tional study and include evaluation of immune response
biomarkers in blood and tumor biopsies, characterization
of extracellular vesicles in the blood, analysis of cell death
biomarkers in blood and investigation of the microbiome
in feces samples (see Additional file 1).
Fig. 1 Proposed mode of action of the combination treatment. (1) Immunogenic cell death, resulting in tumor antigen (TAA) release and
production of danger-associated molecular patterns (DAMPs), is induced by radiation, low-dose cyclophosphamide, curcumin and vitamin D. (2)
The released TAA can be taken up by immature dendritic cells (DC) for processing through the antigen processing machinery. In the presence of
DAMPs, DCs will mature and (3) migrate to tumor-draining lymph nodes to prime antigen-specific CD4+ and CD8+ T lymphocytes. (4) The
primed, tumor-specific CD4+ and CD8+ T cells enter the bloodstream and undergo clonal expansion. (5) Radiation induces chemokine secretion
to recruit the tumor-specific CD4+ and CD8+ T cells into the tumor to kill tumor cells. However, these chemokines also attract inhibitory cells into
the TME. (6) Primed, tumor-specific CD4+ and CD8+ T cells can be inhibited by several mechanisms, which we aim to counter with repurposed
drugs. Tumors maintain an acidic microenvironment by the production of protons and lactate and T cells become dysfunctional in this acidic
environment. Lansoprazole will induce buffering of the extracellular pH by inhibiting vacuolar H+-ATPase resulting in proper functioning of T cells.
The tumor vasculature is abnormal, leading to hypoxic regions in which T cells become dysfunctional. Low-dose cyclophosphamide, vitamin D
and aspirin will remodel the tumor vasculature to improve T cell functioning. Tumor cells release immunosuppressive cytokines, which might be
exacerbated by radiation, and leads to recruitment of myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM), which
inhibit T cells. Aspirin and curcumin will counter some of these cytokines such as PGE2 and vitamin D inhibits myeloid suppressive cells and IL-6,
thereby improving T cell function. Tumors are often infiltrated by regulatory T cells (Treg) capable of inhibiting CD8+ T cells, which can be
exacerbated by radiation. Low-dose cyclophosphamide can inhibit the suppressive activity of Treg, thereby improving the T cell response. (7)
Upon activation, primed CD4+ and CD8+ T cells start to express PD-1, which can be ligated by its ligand PD-L1 on tumor cells or tumor-
infiltrating immune cells, thereby limiting their effector functions. This phenomenon can be countered by pembrolizumab. Also curcumin could
inhibit inflammation-mediated PD-L1. RT: radiotherapy, DAMP: danger-associated molecular pattern, APC: antigen-presenting cell, TME: tumor
microenvironment, Treg: regulatory T cell, MDSC: myeloid-derived suppressor cell
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Trial design
The study is a Phase II multi-center, open-label,
non-randomized, 3-cohort study with a safety run-in in
patients with advanced and/or refractory CC, EC or US.
Even though each treatment separately has well known
and tolerable safety profiles, safety of this particular com-
bination will be determined. The safe dose is defined by 0
or 1 unmanageable dose limiting toxicity (DLT) observed
in the first 6 patients within 30 days after the last RT dose
irrespective of the tumor type. If 2 or more unmanageable
DLTs occur, a new cohort of 6 patients will be recruited.
The drug for which the adverse event is expected in the
highest percentage of patients will first be adjusted in
dose. If toxicity cannot be attributed to one drug, multiple
drugs may become reduced in dose. Dose adjustments will
continue until a safe dose is determined.
The study has an independent data safety monitoring
board (DSMB) consisting of two radiotherapists, one med-
ical oncologist, one gynecologist and one statistician. Aside
from monitoring the safety, validity and integrity of the data
from the study, the DSMB will evaluate the pace of recruit-
ment and will make recommendations to the sponsor
regarding the continuation, modification or termination of
any or all arms of the study. Meetings will be planned every
10th patient. Bimetra Clinics, the clinical research center of
the sponsor institute, will monitor this trial at several time
points and at least before planned data analysis.
Study population
Inclusion criteria
 Histologically confirmed CC, EC or US, refractory
or persistent to chemotherapy or recurrent disease
after at least 1 line of chemotherapy.
 Written informed consent.
 Age 18 years or older.
 Presence of an index lesion amenable to
hypofractionated RT.
 At least 1 lesion outside the RT field for clinical
response assessment.
 Willing to provide tissue from a newly obtained
biopsy of a tumor lesion before and after RT if
technically feasible.
 ECOG Performance status 0–2.
Table 1 Adequate organ function laboratory values
System Laboratory Value
Hematological
Absolute leukocyte count ≥2500 /mcL
Absolute lymphocyte count (ALC) ≥500 /mcL
Absolute neutrophil count (ANC) ≥1500 /mcL
Platelets ≥100,000 / mcL
Hemoglobin ≥9 g/dL or ≥ 5.6 mmol/L without transfusion or
EPO dependency (within 7 days of assessment)
Renal
Serum creatinine ≤1.5 X upper limit of normal (ULN)
OR OR
Measured or calculateda creatinine clearance
(GFR can also be used in place of creatinine or CrCl)
≥60 mL/min for subject with creatinine
levels > 1.5 X institutional ULN
Hepatic
Serum total bilirubin ≤ 1.5 X ULN
OR OR
Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN
AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR
≤ 5 X ULN for subjects with liver metastases
Albumin > 2.5 mg/dL
Coagulation
International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant
therapyas long as PT or PTT is within therapeutic
range of intended use of anticoagulants
Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy
as long as PT or PTT is within therapeutic range
of intended use of anticoagulants
aCreatinine clearance should be calculated per institutional standard
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 Patients treated with a proton pump inhibitor or
anti-coagulant should switch to the study regimen
during the trial.
 Demonstrate adequate organ function as defined in
Table 1.
 Female subjects of childbearing potential should
have a negative pregnancy test and must use
contraception.
Exclusion criteria
 Currently participating or has participated in a study
of an investigational agent within 4 weeks of the first
dose of treatment.
 Diagnosis of immunodeficiency or receiving
immunosuppressive therapy
 Prior chemotherapy, targeted small molecule/
antibody therapy, hormonal therapy or radiation
therapy within 4 weeks prior to study.
 Known additional malignancy that requires active
treatment.
 Known active central nervous system (CNS)
metastases and/or carcinomatous meningitis.
 Active autoimmune disease.
 History or evidence of active, non-infectious
pneumonitis.
 Active infection requiring systemic therapy.
 Prior therapy with an anti-PD-1, anti-PD-L1, or
anti-PD-L2 agent.
 Known history of TB (Bacillus Tuberculosis),
Human Immunodeficiency Virus (HIV), Human T
cell Lymphotropic Virus (HTLV), syphilis, Hepatitis
B or Hepatitis C.
 Subjects have received a live vaccine within 30 days
of planned start of study therapy.
Treatments and interventions
Treatments
The treatment consists of an induction phase where pa-
tients receive the combination of immune-modulatory
repurposed drugs (vitamin D, aspirin, lansoprazole),
metronomic chemotherapy (low-dose cyclophospha-
mide) and the food supplement (curcumin) for 2 weeks.
Thereafter, the first dose of pembrolizumab (200mg) is
administered before the first hypofractionated RT (8 Gy)
to 1 index lesion. RT is given twice (8 Gy) more with a
48-h interval. RT details are described in the Additional
file 1. Pembrolizumab (200 mg) is repeated every 3 weeks
for a total of 6 cycles. The immune-modulatory combin-
ation is given continuously until week 26, the time of
primary endpoint measurement. A detailed overview can
be found in the study scheme (Fig. 2). Patients with clin-
ical benefit (SD, PR, CR as BOR) can continue pembroli-
zumab (200 mg, Q3W) for up to 2 years, according to
article 34 of the Declaration of Helsinki on post-trial
access to study medication. Treatment with the immu-
nomodulatory cocktail may be continued upon investi-
gators’ choice. To aid patient adherence to this complex
Fig. 2 Schematic study design. RT: radiotherapy
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treatment, patients receive a diary and only sufficient
medication is provided until the next hospital visit. Con-
cerning the immune-modulatory combination, we opted
to add an extra drug or food supplement every 24 h until
the complete combination is taken during the first week
of the induction phase for safety reasons. Thereafter, the
combination is taken as described in the treatment
schedule (Table 2).
Table 2 Trial treatment schedule
Drug Dose/Potency Frequency Time of oral
intake
Route of
Administration
Treatment Period Remarks
8
h
12
h
18
h
20
h
Pembrolizumab
(Keytruda)
200 mg Q3W IV infusion Day 1 of each 3-week
cycle
May be discontinued upon
unacceptable toxicity
Administration should be
withheld for drug-related
non-hematologic toxicity ≥
grade 2 (excluding fatigue)
Use corticosteroids for irAE
Radiation 8 Gy 3 fractions
48 h apart
Day 1, 3 and 5 of
Pembrolizumab cycle 1
See Additional file 1
Vitamin D3 (D-Cure) 2000 IU (50 μg) a Daily X Oral Daily from day −14 Intake of other vitamin D
preparations should be
stopped
Blood should be monitored
for calcium and phosphate
Caution in patients
receiving digitalis
preparations
Lansoprazole
(Lansoprazole Teva)
180 mg (uneven
weeks);
30 mg
(even weeks) b
Daily X X c Oral Daily from day −12 Needs to be taken at least
30 min before a meal
Patients taking any kind of
proton pump inhibitors
should switch to Lansoprazole
Teva throughout the study
period
Must be taken 2 h apart from
all other orally administered
drugs
Aspirin (Sedergine) 325 mg d Daily X Oral Daily from day −11 Patients receiving any other
anti-coagulant therapy should
switch to Sedergine throughout
the study
Cyclophosphamide
(Endoxan)
50 mg e Daily X Oral Daily from day −10 Monitor leukocyte levels
regularly during treatment
Do not administer to patients
with leukocyte levels < 2500/μl
and/or thrombocyte levels
of < 50,000/μl
Consumption of grapefruit and
its derivatives is counter-advised
Curcumin (CurcuPhyt)
(Food supplement, NIMP)
2 g f Daily X X Oral Daily from day −13 Patients are suggested to
not take H2
Beta blockers
(beta-adrenoreceptor
antagonists)
Proton pump inhibitors
should be
consumed 2 h apart
Patients should not consume
other turmeric containing food
a30 drops should be resolved in fat-containing drink, e.g. milk
b Capsules should be swallowed entirely with fluid
c uneven weeks only
d Effervescent tablets should be dissolved in water
e Tablets should be taken with a large amount of fluid.
f Capsules should be taken with a meal and not be chewed on
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Interventions
The study flow chart (Fig. 2 and Additional file 1: Table
S1) tabulates the timing of all scheduled drug adminis-
trations, blood samplings and tumor imaging procedures
throughout the study to document safety and efficacy of
the treatment.
For the exploratory translational research, blood, bi-
opsy and feces collections take place at different time
points during the study.
The details of the exploratory translational research
analyses are described in detail in the Additional file 1.
Sample size
The total sample size consists of both evaluable and
non-evaluable patients. Evaluable patients are defined as
patients who received at least all components of the
treatment, being 2 weeks of immunomodulatory com-
bination, 1 dose of pembrolizumab and the 3 radiother-
apy fractions. The study will continue until the
necessary number of evaluable patients is reached. Pa-
tients included in the safety run-in will be part of the ef-
ficacy analysis to fasten inclusion. However, each cohort
will be analyzed separately and no comparison between
disease types will be made. The sample size is calculated
based on a two-stage design using exact binomial tests.
Estimated numbers of CC and EC patients needed to
achieve the primary study objective and the clinical and
statistical assumptions made can be found in Table 3.
For the US group, no sample size calculation is per-
formed due to the rarity of the disease. However, to pro-
vide these patients with a possibly effective treatment
option, these patients will be allowed on study. These
data will provide an indication for possible further devel-
opment of this treatment in uterine sarcoma.
Data analysis
The CC and EC groups will be analyzed separately. No
correction for multiple testing will be applied. Only de-
scriptive statistics will be provided for the uterine sar-
coma group.
Primary endpoint
Patients with complete or partial response at week 26
according irRC criteria will be regarded as responders.
Patients for whom the scheduled tumor imaging at week
26 is not available will be considered to be a
non-responder for the primary analysis.
The null hypothesis that the true response rate π is
10% will be tested against a one-sided alternative (Ha:
π > 10%). A point estimate with a 90% confidence inter-
val will be reported.
Secondary endpoints
Safety The number of unmanageable dose limiting tox-
icities will be reported for the run-in period and the
main trial. The number of patients with AEs, serious
AEs (SAEs) and treatment-related AEs will be summa-
rized by system organ class and preferred term and by
worst toxicity grade. Laboratory safety and other safety
assessments will be described descriptively by visit and
the difference with the baseline visit for all other visits
for each group separately.
Response rate at week 26 according to RECIST
The ORR at week 26 according to RECIST will be ana-
lyzed similarly as the primary endpoint.
Best overall response The BOR is defined as the best
response (confirmed complete or partial response, per
RECIST v1.1) recorded from the start of the study treat-
ment at any time during the study taking into account
any requirement for confirmation. It will be analyzed
similarly as the primary endpoint.
Progression-free survival The PFS, defined as the time
from start of treatment until progression or last follow-up,
will be analyzed as interval censored data by means of the
Turnbull estimate. Patients without progression will be
censored at their last visit. At weeks 26, 52, 75, 104, 130
and 156 the proportion of progression-free patients will
be estimated with a 95% confidence interval and median
PFS will be calculated.
Overall survival The OS, defined as the time from start
of treatment until death, will be analyzed by means of a
Kaplan-Meier estimate. Patients who survived will be
censored at their last visit. At weeks 26, 52, 75, 104, 130
and 156 the proportion of patients surviving will be
Table 3 Statistical sample size calculation
Null hypothesis
(H0)
Total number of patients
required
Number of responses needed for H0
rejection
Alternative
hypothesis
Type I
error
power
Cervical cancer π > 10% 18 5 π =35% 5% 80%
Endometrial
carcinoma
π > 10% 25 6 π =30% 5% 79.3%
Uterine sarcoma No sample size calculation is performed due to the rarity of the disease, but these patients will be allowed on the study
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estimated with a 95% confidence interval and median
OS will be calculated.
Quality of life Quality of life will be measured by
FACT-Cx questionnaire for the CC group and by the
FACT-G questionnaire for the EC and US groups. De-
scriptive statistics of the total score at each visit and the
difference with the baseline visit for all other visits will
be reported.
Exploratory endpoints
The explorative endpoints will be described descriptively
by visit and the difference with the baseline visit for all
other visits for each group separately. They will be re-
lated to the primary endpoint, ORR at week 26 accord-
ing to RECIST, BOR, PFS and OS.
Subgroup analyses
For all primary and secondary endpoints subgroup ana-
lysis is planned. This is exploratory and not statistically
powered. For CC, squamous versus non-squamous
histology, HPV-positive versus HPV-negative tumors
and PD-L1 status will be evaluated. For EC, endome-
troid versus non-endometroid histology, grade 1 ver-
sus grade 2/3 tumors, MSI versus MSS, hormone
receptor positive versus negative, PTEN deficient
versus wild-type, and wild-type POLE versus proof-
reading mutant POLE status will be analyzed. For
both CC and EC, correlation with absolute lympho-
cyte count before treatment and at 0, 1 and 3 months
after the first pembrolizumab administration will be
evaluated. Subgroup analysis is based on the etiology
of each cancer type.
Comparison for all primary and secondary endpoints
between the subgroups will be done by a Fisher’s Exact
test.
Comparison for PFS between the subgroups will be
done by means of the generalized logrank test of Sun.
Comparison for OS between the subgroups will be
done by means of the logrank test.
Discussion
Although ICB has led to remarkable response rates in
some subtypes of uterine cancers, the majority of pa-
tients with recurrent CC, EC or US do not benefit from
single-agent ICB, urging for the development of more ef-
fective therapeutic regimens for these patients. We
hypothesize that combining PD-1 blockade with radio-
therapy and additional immune modulators might result
in clinical responses in about one third of patients. The
combination with repurposed compounds is also of im-
portant economical value, as opposed to combinations
with novel, expensive drugs that are posing financial tox-
icity to the healthcare systems [49–53]. In the current
study, we aim to assess the efficacy of this novel combin-
ation treatment in recurrent CC, EC and US. The
innovation of this study originates from the combined
use of 7 treatments to simultaneously act on tumor me-
tabolism, angiogenesis and anti-tumor immunity. In
addition, the translational research focused on immuno-
logic markers, extracellular vesicles, cell death bio-
markers and alterations in the gut microbiome might be
suitable to identify mechanisms of response and resist-
ance to therapy, resulting in predictive biomarkers for
efficacy and improved patient selection in future clinical
applications.
Additional file
Additional file 1: 1. Additional data. 2. Additional Tables. Table S1: Trial
flowchart. Table S2: Planned immunological analyses. (DOCX 95 kb)
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